ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-25

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates whether healthcare providers without specialized ultrasound training can use UltraSight's machine learning based Guidance Software to perform limited transthoracic echocardiography in patients with hypertrophic obstructive cardiomyopathy (HOCM), who are receiving or eligible for mavacamten (Camzyos™). Participants will undergo two heart scans on the same day, one by a non-sonographer using the software and one by a trained sonographer. The study aims to determine if the software-guided images are comparable in quality, with the goal of expanding access to heart monitoring for HCM patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study for the Assessment of the Quality of Echocardiographic Clips.

NCT05090748

Cardiac Disease

COMPLETED

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

NCT07263204

Hypertrophic Cardiomyopathy (HCM) Left Ventricular Hypertrophy

RECRUITING

Diagnosis of HCM With AI-ECG

NCT06287892

Hypertrophic Cardiomyopathy

RECRUITING

Safety and Efficacy Study of AI LVEF

NCT05140642

Heart Failure, Systolic Heart Failure, Diastolic

COMPLETED NA

Optimization of an Automated Ultrasound Cardiac Guidance Tool

NCT04981444

Ultrasound Therapy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is evaluating whether healthcare providers without specialized ultrasound training can use UltraSight's Guidance Software to perform heart ultrasound exams (limited transthoracic echocardiography) in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are receiving or eligible for treatment with Camzyos™ (mavacamten). The study aims to determine if the software-guided images are comparable to those taken by the sonographers, in quality. Participants will receive two echocardiography scans on the same day (one by a non-sonographer using UltraSight's Guidance Software and one by a sonographer), and the image quality will be reviewed by expert cardiologists. The study aims to increase patients' access to cardiac monitoring, especially for this patient population, by enabling more healthcare professionals to perform these echocardiography exams safely and effectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy (HCM) Cardiac Imaging Echocardiography Mavacamten Obstructive Cardiomyopathy, Hypertrophic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertrophic obstructive cardiomyopathy (HOCM) Patients Undergoing two Echo Exams

Hypertrophic obstructive cardiomyopathy (HOCM) patients who are eligible for or currently receiving Camzyos™ (mavacamten) will undergo two limited transthoracic echocardiography (LTTE) exams on the same day: one performed by a trained sonographer, and the other by a non-sonographer healthcare provider using the UltraSight Guidance Software. The study will compare the image quality and diagnostic agreement between the two sets of scans to evaluate the software's ability to support non-experts in performing cardiac ultrasound.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects aged 18 years or over at the time of screening.
2. Willing and able to give written informed consent.
3. New York Heart Association (NYHA) Class I to III
4. Eligible to receive or currently receiving CamzyosTM per product labelling.

Exclusion Criteria

1. Emergency (non-elective) admission within 24 hours prior to participating in the study.
2. Unable to lie down as required in all the classic positions for standard TTE exam: supine on back/left decubitus.
3. Subjects who had technically difficult exam in the past, due to body habitus, upon investigator's discretion.
4. Subjects with body mass index (BMI) above 40 kg/m2.
5. Subjects experiencing a known or suspected acute cardiac event.
6. Subjects with severe chest wall deformities as per previous medical records and physical examination.
7. Subjects who have undergone pneumonectomy.
8. Subjects whose anatomy does not lend itself to yield diagnosable echocardiography clips (i.e., situs inversus with dextrocardia, single ventricle anatomy due to congenital heart defect, etc.).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No